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1. Introduction  
Ginkgo biloba is an ancient Chinese tree, appeared more than 250 million years ago, and the 
only surviving member of Ginkgoacea family [Schmid, 1997]. Ginkgo biloba was used as 
herbal remedy for many centuries in China, and now its extracts are one of the most widely 
used herbal products in the world, especially in the United States and in Europe 
[Blumenthal, 2000; Mahadevan & Park, 2008]. Ginkgo biloba extract is considered an 
alternative medicine for the treatment and/or the prevention of different pathologies and in 
some cases it could be suggested to be used as complementary of the mainstream medicine 
[Ernst, 2000]. In fact, over the past decades, there was a steady growth trend in the use of 
these alternative treatments. In particular, concentrated and partially purified products, 
containing Ginkgo biloba active constituents, have been marketed widely in the world for the 
treatment of cognitive deficits and other age-associated impairments [Kanowski et al., 1996; 
Le Bars et al., 1997]. Furthermore, it has been used as therapeutic compound for many other 
chronic and acute forms of diseases such as cardiovascular and bronchial pathologies 
[Diamond et al., 2000].  
In view of the large market as well as the keen interest in the use and rediscovery of these 
herbal products throughout the world, the quality control of Ginkgo biloba extracts becomes 
necessary, in order to guarantee their clinical efficacy and safety. Therefore, it is important 
to monitor simultaneously the bioactive constituents present in Ginkgo biloba extracts, 
optimizing the analysis time and reducing costs. In fact, in the recent years, numerous 
groups reported in literature different analytical methods, using various chromatographic 
conditions and spectophotometric technologies, to create quick, accurate and applicable 
analytical approaches for the identification and the chemical structure characterization of 
Ginkgo biloba constituents. 
Ginkgo biloba extracts contain a large number of representative constituents such as 
terpenoids, polyphenols, allyl phenol, organic acids, carbohydrates, fatty acids and lipids, 
inorganic salts and amino acids. However, the pharmacological activity of Ginkgo biloba 
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extracts was attributed to the synergistic action of two distinct classes of chemical 
compounds, the flavonoids and the terpene trilactones [Sticher, 1993; Stiker et al., 2000; Li & 
Fitzloff, 2002a; Van Beek, 2002; Smith & Luo, 2004]. The flavonoids comprise a large group 
of polyphenols and include flavone and flavonol glycosides, acylated flavonol glycosides, 
biflavonoids, flavan-3-ols and proanthocyanidins. Of these, flavonol glycosides are more 
abundant than the other ones. Moreover, numerous flavonol glycosides were identified in 
Ginkgo biloba extracts as derivatives of the aglycones such as quercetin, kaempferol and 
isorhamnetin that are usually present in the leaves in relatively small amounts [Haslet et al., 
1992; Van Beek, 2002]. The flavonoids are known to act mainly as antioxidants [Goh et al., 
2003], free radical scavengers [Ellnain-Wojtaszek et al., 2003] and cation chelators [Gohil & 
Packer, 2002]. Finally, they could play a protective role in the prevention of certain kind of 
cancer as suggested in different studies on animal models [Kuo, 1997; Kandaswami et al., 
2005]. 
The second group is represented by the terpene trilactones, which include diterpenoid 
(ginkgolides) and a sesquiterpenoid (bilobalide) compounds. Ginkgolides A, B, C, J, K, L 
and M are potent and selective antagonist of platelet activating factor (PAF) [Braquet, 1987; 
Van Beek et al., 1991; Smith et al., 1996; Hu et al., 1999]. PAF is an endogenous and highly 
active mediator of inflammation in the human body; it is produced by a variety of 
inflammatory cells and for this reason it is implicated in various disease states. So, the 
ginkgolides, used as the PAF antagonist, are able to prevent and treat thrombosis, illness of 
blood vessel of heart and brain, arhythmia, asthma, bronchitis and allergic reactions 
[Chavez & Chavez, 1998; Sticher, 1999; Diamond et al., 2000; Koch, 2005].  
On the other hand, the sesquiterpene bilobalide exhibits neuroprotective properties 
[Chandrasekaran et al., 2001; Defeudis, 2002]. It is widely employed to treat symptoms 
associated with mild-to-moderate dementia, impairment of other cognitive functions 
associated with ageing and senility and related neurosensory problems [Blumental et al., 
2000]. In fact, numerous studies, based on in vivo models, indicated that the administration 
of bilobalide can reduce cerebral edema due to triethyltin, decrease cortical infarct volume 
as verified in certain stroke models and reduce damage caused by cerebral ischemia 
[Chandrasekaran et al., 2001; Defeudis, 2002]. 
All the mentioned pharmacological actions of the compounds isolated from Ginkgo biloba 
were clarified over the years and helped to highlight the diversity of their potential activities 
on human health. In particular, in the present chapter we focused our attention to review 
the neuroprotective role of Ginkgo biloba extracts. In fact some publications, reporting the 
pharmacokinetic behaviours and in vitro and in vivo clinical results of Ginkgo biloba extracts, 
shown that they are an important ingredient to treat cognitive disturbance, although the 
molecular mechanism of their action is still ambiguous. In particular we examined 
bilobalide, the bioactive compound of Ginkgo biloba that is probable the principal responsible 
for this effect. 
Finally, this chapter aims to provide an overview on the main techniques and methods used 
for the assay of Ginkgo biloba components. 
2. Neuroprotective properties of Ginkgo biloba extracts and Bilobalide 
Gingko biloba extract (GBE) presents a wide range of biological/therapeutical effects. 
Concerning its pharmacological activity on the central nervous system it seems due to 
synergic action of its main constituents: flavonoid-glycosides and terpene-lactones. 
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The investigations of neuroprotective effects of Ginkgo biloba have used its standardized 
extract. The extract standardized contains about 24% flavonoid glycosides and 6% terpene 
lactone. 
Specifically Ginkgo biloba extract (GBE) is described to have different biological effects. For 
example, several authors reported that GBE may be a molecular target of amyloid precursor 
protein (APP) [Luo et al., 2002; Agustin et al., 2009; Jin et al., 2009] and it determined 
beneficial effects on brain function. 
Other authors investigated the action of GBE on oxidative damage [Bridi et al., 2001; Naik et 
al., 2006; Sener et al., 2007], specifically in relation to ischemia/reperfusion [Urikova et al., 
2006; Domorakova et al., 2009]. In addition, it is reported that GBE protects against 
mitochondrial dysfunction in platelets and hippocampi [Shi et al., 2010a; Shi et al., 2010b]. 
Ginkgo biloba extract it was also reported to have a positive effect on memory in healthy 
animals [Gong et al., 2006; Yamamoto et al., 2007; Blecharz-Klin et al., 2009] and humans 
[Kennedy et al., 2007]. 
Of course a number of authors concern the effect of GBE on typical neuro-degeneration 
diseases, such as Alzheimer [Agustin et al., 2009; Luo, 2006; Ahlemeyer & Krieglstein, 2003; 
Luo, 2001] and Parkinson [Beal, 2003; Kim  et al., 2004; Ahmad et al., 2005; Chen  et al., 2007; 
Rojas et al., 2008]. 
Regarding the flavonoid fraction of GBE only few studies have been performed and they 
concern prevention of membrane damage caused by free radicals. In particular, flavonoid 
fraction protects cultures of neurons against oxidative stress due to hydrogen peroxide and 
iron sulfate [Sloley et al., 2000], as well as neural tissue against cerebral ischemia lesion 
[Dajas et al., 2003]. Moreover, it was described that flavonoid fraction inhibited sodium 
nitroprusside-induced death in primary hippocampal cultures of rat [Saija et al., 1995], and 
the authors suggested that flavone glycosides, as radical scavengers, block the formation of 
peroxynitrite as a product of NO and superoxide anion reaction. 
Concerning the terpene-lactones, studies mainly regard bilobalide. In vitro and ex vivo 
investigations indicate that bilobalide has multiple actions, such as preservation of 
mitochondrial ATP synthesis [Janssens et al., 1995], inhibition of apoptotic damage 
[Ahlemeyer et al., 1999], suppression of hypoxia-induced membrane deterioration [Klein et 
al., 1997] and increasing the expression of the mitochondrial DNA-encoded COX III 
[Chandrasekaran et al., 2001]. 
Specifically, the sesquiterpene reduces the edema formation in hippocampal slices exposed 
to N-methyl-D-aspartate (NMDA) [Kiewert et al., 2007], or obtained by oxygen-glucose 
deprivation (OGD) [Mdzinarishvii et al., 2007]. The neuroprotective effect of bilobalide is 
partially correlated to its GABAergic antagonism, but it doesn’t fully explain the bilobalide’s 
action [Kiewert et al., 2007]. More recently, it has been reported that glycine, at 10-100 mM 
level, contrasts the effect of bilobalide. In particular, bilobalide reduces the release of glycine 
during ischemia but it does not interact with glycine receptors [Kiewert et al., 2008]. 
Because bilobalide is instable, it has been prepared a stable derivative called NV-31. This 
modified compound resulted to reduce by 50% the cellular ROS content in chick neurons 
submitted to serum deprivation and staurosporine-induced apoptosis [Ahlemeyer et al., 
2001]. Moreover NV-31 has been reported to potentiate hippocampal neuron recombinant 
glycine receptor Cl channels [Lynch & Chen, 2008]. 
The protective effect of bilobalide against convulsion was observed by Sasaki et al. (2000) 
using 4-O-methylpyroxidine (MPN) for changing the levels of gamma-aminobutyric acid 
(GABA) and glutamic acid decarboxylase (GAD) activity in hippocampus cerebral cortex. 
www.intechopen.com
 Biomedical Engineering, Trends, Research and Technologies 
 
366 
Finally, gingkolide B (GB) was used in neuroprotective studies. In particular, this terpen-
lactone reduced up-regolation of constitutive and inducible nitric oxide synthase in 
hyperthermic brain injury [Sharma et al., 2000]. 
3. Structural characterization of Ginkgo biloba′s main compounds  
Ginkgo biloba is characterized by the presence of numerous constituents belonging to 
different chemical classes, which are well investigated over the years. In fact, there are many 
studies that report the various groups of components present in its extracts [Van Beek, 2002; 
Singh et al., 2008; Van Beek & Montoro, 2009]. However, depending on their chemical 
structures, the major bioactive compounds can be classified into two groups: flavonoids and 
terpene lactones [Li & Fitzloff, 2002a; Li & Fitzloff, 2002b].  
The flavonoids, also called phenylbenzopyrines or phenylchromones, comprise a large 
group of structurally related compounds, characterized by the presence of two aromatic 
rings and a heterocyclic ring with one oxygen atom; this group include flavonol glycosides, 
biflavonoids, biflavones, proanthocyanidins and isoflavonoids. Specifically, the flavonoids 
most commonly present in Ginkgo biloba extracts are the flavonol glycosides, in which one or 
more hydroxyl group of the aglycones are bound to a carbohydrate moiety, usually via the 3 
or 7 position (Fig.1). Numerous flavonol glycosides were identified as derivatives of the 
phenolic aglycones (quercetin, kaempferol or isorhamnetin) that, when alone, are present in 
relatively low concentration [Hasler et al., 1992; Sticher, 1999]. However, the Ginkgo biloba 
contains also a large number of biflavonoids, which are flavonoid–flavonoid dimers 
connected by a C–O–C or C–C bond. 
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Fig. 1. Structural skeleton of flavonoids. 
Terpene lactones include 20-carbon diterpene lactone derivatives (ginkgolides) and a 15-
carbon sesquiterpene (bilobalide). These compounds are the unique natural products to 
possess a tert-butil group in their structure [Van Beek, 2005) (Fig.2). In particular, 
ginkgolides contain a rigid carbon skeleton consisting of six fused 5-membered carbocyclic 
rings, that is, a spiro [4.4] nonane carbocyclin ring, three lactones and a tetraydrofuran. On 
the contrary bilobalide has a more flexible structure containing only 5-membered rings 
[Nakanish et al., 1971]. 
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Fig. 2. Chemical structures of the terpene trilactones of Ginkgo biloba extract.  
By far the terpene lactones received a great attention for the chemical uniqueness, due to 
their cage like structure. Ginkgolide A, B, C and M were isolated for the fist time from 
Ginkgo biloba root bark and described by Furukawa in 1932 (1932), and only later, 
ginkgolides A, B and C were reported to be present in the leaves too. Ginkgolide J was 
identified, by Weings et al. in 1987 (1987), as a minor constituent present in the leaves of 
Ginkgo biloba. In addition, Wang et al. (2001) reported the identification of other two 
ginkgolides (K and L) containing a further double bond. In fact, Yuan et al. (2008) recently 
described ginkgolide K as the dehydrated form of ginkgolide B. Similarly, ginkgolide L 
should derived from the dehydratation of ginkgolide A, although this hypothesis is not 
confirmed in literature.  
A thorough mass spectrometric investigation of this class of compounds is very important 
for their identification and characterization.  
The fragmentation pathway of bilobalide observed in our laboratory is shown in Fig.3. It 
was based on data obtained by means of LC-MS/MS analysis with an APCI source and an 
ion trap analyzer (ITMS), in negative ion mode. These results are in good agreement with 
those observed by Sun et al. (2005) using an electrospray interface. Instead, the 
fragmentation of bilobalide obtained by LC-ESI-MS/MS using a triple quadrupole (QqQ) 
analyzer, shows differences related to the relative abundances of the fragmented ions. 
Specifically, the most abundant fragments are m/z 163 and 251 from QqQ and ITMS, 
respectively.  
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Fig. 3. a) APCI-MS and b) APCI-MS/MS spectra of [M-H]¯ at 325 m/z. 
Table 1 reports the fragmentated bilobalide ions obtained by ion trap and triple quadrupole. 
In particular, ion product at m/z 325 is due to the loss of a ter-butyl and a hydroxyl group, 
while fragmentation at m/z 163 is related to the loss of two carbon dioxide molecules. 
 
% relative abundance 
HPLC/ESI-MS/MS 
HPLC/APCI-
MS/MS 
Ion Bilobalide m/z 
[Sun et al.; 2005]  
[M-H]¯ 325 30 6 
[M-H-CO2]¯ 281 0 4 
[M-H-2CO2]¯ 237 25 36 
[M-H-3CO2]¯ 193 30 8 
[M-H-2CO-H2O]¯ 251 30 100 
[M-H-CO-H2O-2CO2]¯ 206 10 14 
[M-H-2CO-H2O-2CO2]¯ 163 100 2 
Table 1. Comparison of the major product ions of the bilobalide obtained by using ESI-
MS/MS and APCI-MS/MS methods. 
On the other hand, the ginkgolides show fragmentation pathways similar among them. 
Generally, the most favourable fragmentation way of the deprotonated ginkgolides is the 
loss of single and multiple carbon monoxide molecules. In each cases, the most abundant 
fragment ion derived from the loss of two carbon monoxide molecule, [M-H-2CO]¯. For 
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example the MS/MS spectrum obtained from the ginkgolide A molecule ion [M-H]¯  407 m/z 
gives a prominent ion product at m/z 351, resulting from the loss of two carbon dioxide 
molecules and a three less intense product ions at m/z 379, 363 and 319 due to the loss of one 
carbon monoxide molecule, one and two molecules of carbon dioxide, respectively [Van 
Beek, 2005; Sun et al., 2005].  
4. Analytical methods for quality control of Ginkgo biloba extracts 
Chemical fingerprint analysis represents a comprehensive approach for the quality 
assessment purpose of traditional Chinese herbs. In fact, most herbal medicines are complex 
mixtures whose therapeutic effect is often attributed to the cumulative effects of many 
components. For this reason, it is important to achieve an overall view of all the components 
present in the extracts to evaluate the quality of the plant products. Moreover, it is necessary 
and important to develop a reliable and applicable quality control method for the 
constituents present in most herbal extracts. To this end, different analytical methods are 
proposed for the quality and the stability evaluation of herbal medicines.  
As described above, for the analysis of the flavonoids and terpene lactones, the main 
bioactive compounds present in Ginkgo biloba extracts, the scientific literature report a lot of 
methods. The great number of these methods is based on high-performance liquid 
chromatography (HPLC) coupled to UV [Pietta et al., 1990; Pietta et al., 1992; Hasler, et 
al., 1992], refractive index (RI) [Van Beek et al., 1991; Chen et al., 1998; Wang & Ju, 2000], or 
ELSD [Li & Fitzloff, 2002] detection and gas chromatography (GC) combined to flame 
ionisation (FID) [Huch & Staba, 1993; Van Beek, 2002; Yang et al., 2002] or mass 
spectrometry (MS) [Chauret et al., 1991; Deng & Zito, 2003] detection. 
High-performance liquid chromatography coupled to the ultra-violet detection (HPLC-UV) 
is the technique of choice for the fingerprinting analysis of the total flavonoids of Ginkgo 
biloba L. extracts [Hasler et al., 1992], while it presents several limitations for the qualitative 
and quantitative determination of terpenes, due to their low UV absorption and the 
impurities present in the complex matrix of Ginkgo biloba L. extracts. However, Pietta et al. 
(1990; 1992) described a new procedure for the preparation of samples that, using HPLC 
combined to UV detector, permits the identification of terpene compounds of Ginkgo biloba 
L. extracts. In particular, in the study proposed by Pietta et al. in 1990 was developed an 
efficient method for the purification of terpene compounds in Ginkgo biloba L. extracts based 
on the separation of the ginkgolides fractions by means of prepacked alumina columns. The 
resulting cleaned samples were separated by isocratic elution on Microsorb C18 columns 
(analytical: 100 x 4.6 mm i.d., 3µm; Rainin Instrument Co., Woburn, MA, USA – semi-
preparative: 250 x 10 mm i.d., 5 µm; Biolab Instrument) using 10% isopropanol and analyzed 
with an UV photodiode detector. These results show that, combining a new sample 
purification process together with the optimization of the chromatographic conditions, it is 
possible to obtain a simple method suitable for the determination of bilobalide, ginkgolide 
A, B and C in Ginkgo biloba L. extracts.  
Several investigators instead applied refractive index (RI) as an alternative detection method 
[Van Beek et al., 1991; Chen et al., 1998; Wang & Ju, 2000]. As an example, Wang and Ju 
(2000) developed a rapid analytical method that, using HPLC on a C18 column with 
methanol-water-orthophosphoric acid as eluents combined to refractive index (RI) detector, 
permits the quantification of terpene lactones (bilobalide and ginkgolide A, B, C, J) in Ginkgo 
biloba L. extracts in only 20 min of analysis time. This method resulted to be more suitable 
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and was employed with considerable success, although the sensitivity and the baseline 
stability still remain a problem.  
On the contrary, evaporative light scattering detection (ELSD) seems to solve the problems 
related to the baseline stability and permits to reach higher sensitivity, requiring small 
solvent consumption. So, even if it is a non-selective detector, this technique has gained in 
popularity over the last decades, due to its capacity to detect the number and size of non-
volatile compounds. In fact, several papers reported the application of HPLC with ELSD 
detector for the routine determination of ginkgolides and bilobalide [Li & Fitzloff, 2002b; 
Tang et al., 2003; Dubber & Kanfer, 2006]. As an example, Tang et al. (2003), applied RP-
HPLC-ELSD method for the quantitation analysis of terpene lactones in Ginkgo biloba 
extracts. These authors by means of a Dinamic C18 column, using methanol and water 
under isocratic conditions as mobile phase (33:67, v/v), obtained the separation of five 
terpene lactones in 40 min of analysis time (bilobalide and ginkgolide A, B, C, J). This 
method represented a big advantage in terms of selectivity and precision; however the 
narrow linearity intervals (from 100 to 800µg/ml) produced through ELSD response 
represent the major inconvenience of such kind of detectors. 
Another excellent separation technique for terpene lactones is represented by gas-
chromatography coupled to flame ionization detection (GC-FID) [Huch & Staba, 1993; Lang 
& Wai, 1999; Van Beek, 2002; Yang et al., 2002] which is very reliable for the sensitivity and 
reproducibility. However, the sensitivity and selectivity of this separative technique could 
be further increased by the coupling with mass spectrometer detectors (MS) [Chauret et al., 
1991; Biber & Koch, 1999; Deng & Zito, 2003]. Nevertheless GC-based methods require 
complicated and time-consuming sample preparation steps and compound derivatization. 
In the recent years, these problems are solved with the development of several mass 
spectrometry instruments and taking advantage of the combination of these ones with 
HPLC separation systems. In fact, in literature are reported many works in which different 
MS techniques were coupled to HPLC for analysing Ginkgo biloba extracts. 
In particular, different investigators developed HPLC methods combined to MS detection, 
using a thermospray interface (TSP) (Pietta et al., 1994; Caponovo et al., 1995). Briefly, Pietta 
et al. (1994), applied high-performance liquid chromatography interfaced with a 
thermospray ion source mass spectrometer (LC-TSP/MS) for the identification of various 
flavonol glycosides from Ginkgo biloba. While, Caponovo et al. in 1995, employed LC-
TSP/MS analytical techniques for the rapid detection of ginkgo terpene lactones. LC-
TPS/MS method is not very precise due to variability and poor stability of the TSP interface. 
On the contrary, the discovery of the API (atmospheric pressure ionization) interfaces and in 
particular of electrospray ionisation sources (ESI) allowed a soft ionization and a stable 
combination between HPLC separation and MS detection. As reported by Mauri et al. 
(1999), the method based on liquid chromatography coupled with electrospray mass 
spectrometry (LC-ESI-MS) is specific, reproducible, rapid and permits quantitative analyses 
of terpenoids in Ginkgo biloba extracts. In particular LC-ESI-MS method permitted the 
monitory of terpene lactones in Ginkgo biloba extracts by means of quadrupole instrument 
(positive mode) coupled to a C18 columns and 20 min of analysis time in isocratic separation 
[Mauri et al., 1999].  
Similar results were obtained by Jensen et al. (2002) using a triple quadrupole equipped 
with an atmospheric pressure chemical ionization (APCI) interface in the negative ion mode 
and a methanol gradient. For increasing the sensitivity quadrupole needs selectively 
detection of single ion monitoring (SIM).  
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However, in this way, increasing the number of selected ions monitored, the sensitivity 
decreases and it is not possible to monitor unexpected ions. These problems were solved 
with the introduction of ion trap mass spectrometer (ITMS). In fact ITMS present the same 
sensitivity in full scan and SIM modes. Ding et al. (2008a) characterized the flavonoid and 
terpene compounds of Ginkgo biloba products by using a C18 capillary column coupled to 
ion trap MS. The use of the negative ion mode combined to the data depending scan for 
MS/MS acquisition lead to the characterization of more than 70 components from the 
Ginkgo biloba in 140 min of analysis time. As another example Chen et al. (2005) used a 28 
min HPLC separation, based on a C18 analytical column, coupled to sonic spray ionization 
source (SSI) and a mass spectrometer equipped with a ion trap analyzer for characterizing 
terpene lactones constituents from Ginkgo biloba extracts in positive ion mode. On the other 
hand, Mauri et al. (2001) used liquid chromatography/atmospheric pressure chemical 
ionization for coupling HPLC with ion trap mass spectrometry (LC/APCI-IT-MS) to study 
the pharmacokinetics of terpene lactones in human. In particular, in this study 
chromatographic separation was achieved in less than 8 min and calibration curve was 
linear over a concentration range of 5-2000 ng/ml.  
In addition to the ion trap analyzer, Ding et al. (2008b) employed a quadrupole time-of-
flight (QTOF) mass spectrometer for characterizing terpene lactones (bilobalide and 
ginkgolide A, B, C,) in Ginkgo biloba L. extracts [Ding et al., 2008b]. Specifically, the authors 
used both analyzers to obtain two specific goals: ion trap MS for the characterization of the 
terpene fragmentation pathways and QTOF for the estimation of fragment ion mass 
accuracy (3-5 ppm) and the confirmation of the structural identification.  
More recently, in our laboratory, the accurate mass measurement of the Ginkgo biloba 
terpene lactones was performed by means of the Exactive (Thermo Electron Corporation, 
San Josè, CA, USA) a non –hybrid mass spectrometer based on the Orbitrap technology. 
This instrument, equipped with a nanoelectrospray ion source, allows the acquisition of 
accurate mass data together with the improvement of sensitivity. 
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Fig. 4. MS spectra zoom of [M-H]- ions of bilobalide and ginkgolides A,B,C. 
www.intechopen.com
 Biomedical Engineering, Trends, Research and Technologies 
 
372 
Fig. 4 reports the MS spectrum of [M-H]- ions of bilobalide and ginkgolides A,B,C. The full 
scan spectra were acquired at a resolution setting of 100,000 in an infusion experiment 
calibration (i.e. no lock masses were used) and a high dynamic range. In particular, for all 
the terpene lactone ions showed in Fig. 4 it was possible to achieve narrow  peak widths 
with a mass accuracy and a resolving power of around 0,2 ppm and 8 x 105, respectively. 
High resolution, accurate mass measurement together with high dynamic range are 
required for unequivocal characterization of mixtures even in the absence of precursor ion 
mass selection. However, if it is needed, additional informations can be provided by high 
resolution/ high mass accuracy MS/MS experiments in an “all ion fragmentation” mode. 
In fact, the Exactive mass spectrometer allows high efficiency “all ion fragmentation” 
experiments by means of Higher energy Collision induced Dissociation (HCD) [Olsen et al., 
2007]. 
All these performance characteristics make this mass spectrometer well suited for discovery 
analyses, screening applications, quantitative estimation and elemental composition 
determination, solving the limitation of the ion trap technology and representing a good 
alternative to the ion trap based hybrid instruments. 
5. Pharmacokinetic analysis 
Pharmacokinetic and metabolic studies of Ginkgo biloba extracts concern the investigations of 
the main bioactive compounds, flavonoids and terpene-lactones. 
Concerning flavonoids, few metabolic studies are available. In particular, Hackett (1986) 
described correlation between flavonoids and their metabolites using selected standard 
analyzed by means of Thin-layer chromatography (TLC). Of course, TLC technique didn’t 
permit the investigation of complex extracts. Wang et al. (2003) developed a method based 
on liquid chromatography coupled to UV detector (λ=380 nm) for determining kaempferol 
and quercetin in human urine samples after orally administrated Ginkgo biloba extract. 
Other authors used LC-UV and mass spectrometry for characterizing the metabolites of 
flavonoids in rat [Pietta et al, 1995] and human [Pietta et al., 1997] urine samples due to 
administration of standardized Ginkgo biloba extract. The main metabolite resulted to be 
conjugates of 4-hydroxybenzoic, vanillic and 4-hydroxyhippuric acids. 
Recently, Ding et al. (2006) prepared an analytical method, based on ion trap mass 
spectrometry in negative ion mode, for assaying flavonoids in urine from volunteers after 
up-take with Ginkgo biloba extract. In addition, the authors monitored terpene-lactones 
simultaneously elution at a flowrate of 4 µL/min (LOD around 2 and 10 ng/mL for 
flavonoids and terpenes, respectively). This method is interesting, but requires a long 
gradient (> 2 hours) and standard deviation resulted higher than 10%. 
Concerning pharmacokinetics studies of terpene-lactones, many works are available. For 
example Biber [Biber & Koch; 1999] and co-workers [Furtillan et al.; 1995] used gas 
chromatography mass spectrometry for determining, after oral administration, the main 
ginkgolides in plasma from both humans [Furtillan et al., 1995] and rats [Biber & Koch, 
1999]. In particular, in rats the half life of ginkgolides resulted to be around 2 h; at the 
contrary, in human differences were noted for ginkgolide A, ginkgolide B and bilobalide 
(4.5, 10.5, and 3.2 hours, respectively). 
In 2001 Mauri et al. (2001) proposed a fast (within 8 min) method based on atmospheric 
pressure chemical ionization (APCI) interface coupled to an ion trap mass spectrometer to 
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monitor (LOD about 2 ng/mL) terpenes in plasma of volunteers after administration of two 
different Ginkgo biloba formulations (free and phospholipids complex formulations). When 
supplied in the phospholipid complex form, both Cmax and AUC (Area Under the Curve) 
of terpene lactones increased, suggesting that this formulation may increase their 
bioavailability. 
The same approach was extended to investigate pharmacokinetics of terpene-lactones in rats 
and guinea pigs after acute and chronic oral administrations [Mauri et al., 2003]. Other 
authors used APCI interface combined with a triple quadrupole analyzer for investigating 
the bioavailability of ginkgolides after intravenous administration to rats [Xie et al., 2008] 
Specifically, multiple reaction monitoring (MRM) was used and the limit of quantification 
resulted around 2 ng/mL. 
In alternative to APCI, Hua et al. (2006) proposed electrospray interface coupled to Q-array-
Octapole-Quadrupole mass analyzer (QoQ) for investigating the intragastric administration 
of pure ginkgolide B (0.1 ng/kg) in Beagle dogs. The authors reported a LOD around 0.1 
ng/mL while Tmax and t1/2 resulted to be 0.5 h and 2.8 h, respectively. 
Other authors have studied the bioavailability of pure ginkgolide B after oral administration 
and Tmax resulted around 2 and 4 h for phytosomic and free forms, respectively [Mauri et 
al., 2003]. 
Concerning ginkgolide C, different authors observed a very low recovery from plasma of 
this terpene-lactone. This is accompanied by the increase of methylated metabolite observed 
in plasma of both animals and humans [Mauri et al, 2006]. 
All in-vivo studies of terpene-lactones from Ginkgo biloba concern plasma or urine samples. 
However, very recently it has been published a study about the identification of bilobalide 
in rat brain after single oral dose [Rossi et al., 2009]. In particular, it has been observed that 
bilobalide presents different profiles in brain and plasma samples. In fact, in plasma the 
bilobalide levels increase with the administered dose; while the brain levels increase for 
dose up to 10 mg/kg; and decrease for higher doses. These results support the studies that 
described the positive cognitive efforts on brain due to Ginkgo biloba extracts (Lee et al., 2002; 
Kennedy et al., 2007). Moreover the absorption of bilobalide could be explained by a specific 
mechanism of transport and by an inhibition effect due to an overloading of transporter 
after its administration at high doses. 
6. Conclusion 
Ginkgo biloba contains mainly two types of constituents, the flavonoids and terpene lactones, 
which together have been proven to be responsible of the polyvalent activities of Ginkgo 
biloba herbal and Ginkgo biloba–containing preparations. In fact, for many centuries Ginkgo 
biloba was used for the treatment of several pathologies, but in recent years its interest 
increased in relation to the neuroprotective activities ascribed to terpene lactones. To this 
end, the development of many analytical technologies improved fingerprinting authentication 
and quantitative determination of target analytes, as well as the pharmacokinetic and 
pharmacodynamic studies on the active components of Ginkgo biloba and its finished 
products. This is because of selectivity and specificity achieved by both the chromatographic 
and mass spectrometry detection systems. In particular, LC-MS approach appeared to be the 
method of choice for the measurement of target analytes in biological samples. In fact, the 
separation efficiency and fastness of the new HPLC systems combined to the high resolution 
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and accurate measurements of the recent mass spectrometry detectors permit an 
unequivocal characterization of bioactive compounds from Ginkgo biloba extracts. These 
analytical tools will be very important for elucidating the transport and pharmacological in 
vivo mechanisms of terpene lactones and flavonoids. 
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